Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591486405> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2591486405 endingPage "56" @default.
- W2591486405 startingPage "56" @default.
- W2591486405 abstract "56 Background: There are no available imaging biomarkers that can prognosticate for clinical outcomes for patients treated with AA. FDG and FDHT PET demonstrate glucose metabolism and androgen receptor expression, respectively. This is the first study of FDG and FDHT PET as a prognostic biomarker for pts treated with AA. Methods: Pts with progressive metastatic castration resistant prostate cancer (mCRPC) starting AA underwent FDG and FDHT PET scans on an imaging clinical trial. PSA, SUV max (hottest slice of hottest lesion), and SUV maxavg (average SUVmax of 5 index lesions) were collected. An SUV value of 1 was imputed for calculating SUV maxavg in the absence of 5 index lesions. Imaging characteristics were compared to PFS, defined as time to radiographic progression, biochemical relapse or death. The Cox proportional hazards model was used to determine the association between the PET measurements and PFS. The statistics used to measure the association was the concordance probability estimate (CPE). Results: 24 scans sets were obtained. Median pt characteristics were: age 70 (48-85), Gleason score 8 (range 6-10), PSA 85 (2-459). Radiographic and PSA progression occurred in 15/24 (63%), radiographic only 4/24 (17%), and biochemical only 2/24 (9%). 1 pt died on study, 1 elected to discontinue tx, and 1 remains on AA. 16/24 (67%) and 18/24 (75%) of FDG and FDHT PET scans respectively had ≥ 5 hypermetabolic lesions. Median FDG SUV max was 8 (2-15), FDG SUV maxavg 5 (1-11), FDHT SUV max 11 (3-28) and FDHT SUV maxavg 7 (1-16). The correlation between PET measurements and PFS is described (Table). Conclusions: Preliminarily, baseline FDG SUV max and SUV maxavg appear to be prognostic for PFS in pts treated with AA. Higher SUV values prognosticate for a shorter time to progression. Further evaluations of FDG/FDHT PET in mCRPC are underway to better define the role each modality has as a prognostic and response biomarker for AA. Clinical trial information: NCT00588185. [Table: see text]" @default.
- W2591486405 created "2017-03-03" @default.
- W2591486405 creator A5004964677 @default.
- W2591486405 creator A5015289504 @default.
- W2591486405 creator A5015396908 @default.
- W2591486405 creator A5015672299 @default.
- W2591486405 creator A5017288060 @default.
- W2591486405 creator A5031035765 @default.
- W2591486405 creator A5039147214 @default.
- W2591486405 creator A5047583995 @default.
- W2591486405 creator A5050136149 @default.
- W2591486405 creator A5072850546 @default.
- W2591486405 creator A5082878792 @default.
- W2591486405 creator A5090778997 @default.
- W2591486405 date "2014-02-01" @default.
- W2591486405 modified "2023-10-12" @default.
- W2591486405 title "Evaluating 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA)." @default.
- W2591486405 doi "https://doi.org/10.1200/jco.2014.32.4_suppl.56" @default.
- W2591486405 hasPublicationYear "2014" @default.
- W2591486405 type Work @default.
- W2591486405 sameAs 2591486405 @default.
- W2591486405 citedByCount "0" @default.
- W2591486405 crossrefType "journal-article" @default.
- W2591486405 hasAuthorship W2591486405A5004964677 @default.
- W2591486405 hasAuthorship W2591486405A5015289504 @default.
- W2591486405 hasAuthorship W2591486405A5015396908 @default.
- W2591486405 hasAuthorship W2591486405A5015672299 @default.
- W2591486405 hasAuthorship W2591486405A5017288060 @default.
- W2591486405 hasAuthorship W2591486405A5031035765 @default.
- W2591486405 hasAuthorship W2591486405A5039147214 @default.
- W2591486405 hasAuthorship W2591486405A5047583995 @default.
- W2591486405 hasAuthorship W2591486405A5050136149 @default.
- W2591486405 hasAuthorship W2591486405A5072850546 @default.
- W2591486405 hasAuthorship W2591486405A5082878792 @default.
- W2591486405 hasAuthorship W2591486405A5090778997 @default.
- W2591486405 hasConcept C121608353 @default.
- W2591486405 hasConcept C126322002 @default.
- W2591486405 hasConcept C126838900 @default.
- W2591486405 hasConcept C126894567 @default.
- W2591486405 hasConcept C143409427 @default.
- W2591486405 hasConcept C143998085 @default.
- W2591486405 hasConcept C160798450 @default.
- W2591486405 hasConcept C199374082 @default.
- W2591486405 hasConcept C2775832370 @default.
- W2591486405 hasConcept C2775842073 @default.
- W2591486405 hasConcept C2777899217 @default.
- W2591486405 hasConcept C2780192828 @default.
- W2591486405 hasConcept C2989005 @default.
- W2591486405 hasConcept C45664433 @default.
- W2591486405 hasConcept C50382708 @default.
- W2591486405 hasConcept C71924100 @default.
- W2591486405 hasConceptScore W2591486405C121608353 @default.
- W2591486405 hasConceptScore W2591486405C126322002 @default.
- W2591486405 hasConceptScore W2591486405C126838900 @default.
- W2591486405 hasConceptScore W2591486405C126894567 @default.
- W2591486405 hasConceptScore W2591486405C143409427 @default.
- W2591486405 hasConceptScore W2591486405C143998085 @default.
- W2591486405 hasConceptScore W2591486405C160798450 @default.
- W2591486405 hasConceptScore W2591486405C199374082 @default.
- W2591486405 hasConceptScore W2591486405C2775832370 @default.
- W2591486405 hasConceptScore W2591486405C2775842073 @default.
- W2591486405 hasConceptScore W2591486405C2777899217 @default.
- W2591486405 hasConceptScore W2591486405C2780192828 @default.
- W2591486405 hasConceptScore W2591486405C2989005 @default.
- W2591486405 hasConceptScore W2591486405C45664433 @default.
- W2591486405 hasConceptScore W2591486405C50382708 @default.
- W2591486405 hasConceptScore W2591486405C71924100 @default.
- W2591486405 hasIssue "4_suppl" @default.
- W2591486405 hasLocation W25914864051 @default.
- W2591486405 hasOpenAccess W2591486405 @default.
- W2591486405 hasPrimaryLocation W25914864051 @default.
- W2591486405 hasRelatedWork W1979570009 @default.
- W2591486405 hasRelatedWork W2037755209 @default.
- W2591486405 hasRelatedWork W2111347914 @default.
- W2591486405 hasRelatedWork W2117290479 @default.
- W2591486405 hasRelatedWork W2138033649 @default.
- W2591486405 hasRelatedWork W2144454494 @default.
- W2591486405 hasRelatedWork W2790907679 @default.
- W2591486405 hasRelatedWork W2793295628 @default.
- W2591486405 hasRelatedWork W2951337402 @default.
- W2591486405 hasRelatedWork W3197069188 @default.
- W2591486405 hasVolume "32" @default.
- W2591486405 isParatext "false" @default.
- W2591486405 isRetracted "false" @default.
- W2591486405 magId "2591486405" @default.
- W2591486405 workType "article" @default.